AstraZeneca And Sun Pharma Join Forces To Expand Hyperkalaemia Treatment In India

AstraZeneca Pharma India Ltd and Sun Pharmaceutical Industries Ltd have announced a significant partnership aimed at expanding access to hyperkalaemia treatment in India. The collaboration focuses on Sodium Zirconium Cyclosilicate (SZC), a therapy designed to manage dangerously high potassium levels, particularly in patients with chronic kidney disease and heart failure. Under the agreement, AstraZeneca will market SZC as Lokelma, while Sun Pharma will distribute it as Gimliand. AstraZeneca will also receive 260 million rupees from Sun Pharma as part of the deal, reflecting the scale and importance of this alliance.  

Key Highlights  

• Notable updates include AstraZeneca’s receipt of 260 million rupees from Sun Pharma, strengthening its financial position  
• The dual-brand strategy, with AstraZeneca marketing Lokelma and Sun Pharma offering Gimliand, ensuring wider patient reach  
• The therapy’s role in treating hyperkalaemia, a condition linked to chronic kidney disease and heart failure  
• Strategic collaboration aims to improve patient outcomes and expand availability of SZC across India’s healthcare system  

Sources: Business Upturn, InvestyWise, Economic Times